Human recombinant relaxin-2 (serelaxin) regulates the proteome, lipidome, lipid metabolism and inflammatory profile of rat visceral adipose tissue

• DOI: 10.1016/j.bcp.2024.116157
• Publication Date: 2024-03-20T17:29:14Z
• Authors: Alana Aragón-Herrera; Sandra Feijóo-Bandín; Xocas Vázquez-Abuín; Laura Anido-Varela; Sandra Moraña-Fer...; Susana B. Bravo; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Javier García-Seara; José Seijas; Diego Rodríguez-P...; Daniele Bani; Oreste Gualillo; José Ramón Gonzál...; Francisca Lago
• Keywords: Lipidome; Chemerin; Hormone-sensitive lipase; Adipose triglyceride lipase

Recombinant human relaxin-2 (serelaxin) has been widely proven as a novel drug with myriad effects at different cardiovascular levels, which support its potential therapeutic efficacy in several diseases (CVD). Considering these effects, together the influence of on adipocyte physiology and adipokine secretion, connection between visceral adipose tissue (VAT) dysfunction development CVD, we could hypothesize that may regulate VAT metabolism. Our objective was to evaluate impact 2-week serelaxin treatment proteome lipidome from Sprague-Dawley rats. We found increased 1 polyunsaturated fatty acid 6 lysophosphatidylcholines decreased 4 triglycerides employing ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) based platforms, regulates 47 phosphoproteins using SWATH/MS analysis. Through RT-PCR, also caused an effect lipolysis through increase mRNA expression hormone-sensitive lipase (HSL) decrease triglyceride (ATGL), reduction transporter cluster differentiation 36 (Cd36). Serelaxin anti-inflammatory by tumor necrosis factor α (TNFα), interleukin-1β (IL-1β), chemerin, receptor. In conclusion, our results highlight regulatory role lipidome, lipolytic function, inflammatory profile, suggesting implication mechanisms supporting benefit for prevention obesity metabolic disorders.